Pharmacokinetics and safety following a single oral dose of niraparib in patients with moderate hepatic impairment.

被引：0
|
作者：
Akce, Mehmet
El-Khoueiry, Anthony B.
Piha-Paul, Sarina Anne
Bacque, Emeline
Pan, Peng
Zhang, Zhi-Yi
Ewesuedo, Reginald
Gupta, Divya
Milton, Ashley
Judson, Patricia
O'Bryant, Cindy L.
机构：
[1] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Newport Beach, CA USA
[3] Univ Southern Calif, Hoag Mem Hosp, Presbyterian Canc Ctr, Newport Beach, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Program 1, Houston, TX 77030 USA
[5] GlaxoSmithKline, Waltham, MA USA
[6] Univ Colorado, Canc Ctr, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6054
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
    Mehmet Akce
    Anthony El-Khoueiry
    Sarina A. Piha-Paul
    Emeline Bacque
    Peng Pan
    Zhi-Yi Zhang
    Reginald Ewesuedo
    Divya Gupta
    Yongqiang Tang
    Ashley Milton
    Stefan Zajic
    Patricia L. Judson
    Cindy L. O’Bryant
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 825 - 836
  • [2] Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
    Akce, Mehmet
    El-Khoueiry, Anthony
    Piha-Paul, Sarina A.
    Bacque, Emeline
    Pan, Peng
    Zhang, Zhi-Yi
    Ewesuedo, Reginald
    Gupta, Divya
    Tang, Yongqiang
    Milton, Ashley
    Zajic, Stefan
    Judson, Patricia L.
    O'Bryant, Cindy L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (05) : 825 - 836
  • [3] Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment
    Grasela, DM
    Christofalo, B
    Kollia, GD
    Duncan, G
    Noveck, R
    Manning, JA
    LaCreta, FP
    PHARMACOTHERAPY, 2000, 20 (06): : 87S - 94S
  • [4] The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment.
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT.
    Xin, Y.
    Collins, H.
    Cheng, F.
    Kwan, E.
    Ramanathan, S.
    Silverman, J. A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S88 - S88
  • [6] Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
    John Marcinak
    Majid Vakilynejad
    Akifumi Kogame
    Yoshihiko Tagawa
    Drugs in R&D, 2018, 18 : 109 - 118
  • [7] Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
    Marcinak, John
    Vakilynejad, Majid
    Kogame, Akifumi
    Tagawa, Yoshihiko
    DRUGS IN R&D, 2018, 18 (02) : 109 - 118
  • [8] Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration
    Corey, AE
    Agnew, JR
    King, EC
    Parekh, NJ
    Powell, JH
    Thompson, GA
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (05) : 1279 - 1286
  • [9] SINGLE-DOSE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST APROCITENTAN IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT.
    Fontes, M.
    Halabi, A.
    Tomaszewska-Kiecana, M.
    Dinge-Manse, J.
    Sidharta, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S47 - S48
  • [10] SINGLE-DOSE SAFETY AND PHARMACOKINETICS OF APIXABAN IN SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT
    Frost, C. E.
    Yu, Z.
    Wang, J.
    Li, T.
    Zeigler, C.
    Schuster, A.
    Ly, V.
    Zhang, D.
    LaCreta, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S34 - S34
12345